News
ABCL
12.27
-6.19%
-0.81
Weekly Report: what happened at ABCL last week (1026-1030)?
Weekly Report · 3h ago
Is AbCellera Biologics (ABCL) Undervalued On Positive Phase 2 ABCL635 Results?
Simply Wall St · 1d ago
AbCellera initiated with a Buy at Jefferies
TipRanks · 2d ago
Did Positive Phase 2 Results Just Shift AbCellera Biologics' (ABCL) Investment Narrative?
Simply Wall St · 6d ago
Weekly Report: what happened at ABCL last week (1019-1023)?
Weekly Report · 10/26 09:07
Is AbCellera Biologics (ABCL) Undervalued After Encouraging Phase 2 Data For ABCL635?
Simply Wall St · 10/23 13:44
AbCellera to Present at Upcoming Investor Conferences in November 2026
Barchart · 10/22 15:05
AbCellera Biologics Is Up 124% Even As Sales Fell
Simply Wall St · 10/22 11:34
AbCellera Has Promising Menopause Data, But Much Of The Opportunity Is Priced In
Seeking Alpha · 10/22 08:45
Weekly Report: what happened at ABCL last week (1012-1016)?
Weekly Report · 10/19 09:08
After AbCellera Biologics' 125% Climb, The Story Has Changed
Simply Wall St · 10/13 06:22
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
NASDAQ · 10/12 20:25
Weekly Report: what happened at ABCL last week (1005-1009)?
Weekly Report · 10/12 09:08
AbCellera initiated with a Buy at UBS
TipRanks · 10/11 23:35
Is AbCellera Biologics (ABCL) Undervalued After New ABCL635 Data Presentation Plans?
Simply Wall St · 10/11 01:39
Clinical Data Update Might Change The Case For Investing In AbCellera Biologics Stock
Simply Wall St · 10/10 00:29
AbCellera to present Phase 1/2 data for ABCL635 at TMS 2026 Annual Meeting
TipRanks · 10/08 20:11
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Barchart · 10/08 15:05
Weekly Report: what happened at ABCL last week (0928-1002)?
Weekly Report · 10/05 09:08
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Barchart · 10/01 15:05
More
Webull provides a variety of real-time ABCL stock news. You can receive the latest news about Abcellera Biologics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.